HOME >> BIOLOGY >> NEWS
Alcohol consumption during pregnancy alters thyroid function

tal development are similar to brain abnormalities found in children exposed to alcohol in utero. "From a behavioral standpoint," said Cudd, "children born to hypothyroid mothers score less well on intelligence, attention, language, reading ability and school performance measures compared to children born to mothers with normal thyroid function. These deficiencies are similar to those in children with ARBDs. From an anatomical perspective, hypothyroidism and fetal alcohol exposure both affect the development of the hippocampus and the cerebellum." Knowing these similarities, the study authors investigated if ARBDs are, in part, a result of alcohol-mediated thyroid hormone system dysfunction.

Researchers gave pregnant ewes alcohol doses of 0.75, 1.25, 1.5 or 1.75 g/kg or saline through catheters beginning on day 109 of gestation (a full term for sheep is 145 days). The ewes received alcohol or saline on three consecutive days, followed by four days without exposure, thereby mimicking a pattern of binge drinking. Fetal and maternal blood samples were collected on days 118 or 132.

"The administration of alcohol to sheep during the equivalent of the third trimester of pregnancy resulted in altered thyroid function in both the mother and fetus," said Cudd.

"This is an important study because even today so little is known regarding the mechanisms through which alcohol intake by pregnant mothers is bad for their fetuses," said Catherine Rivier, a professor of neuroendocrinology/neurosciences at The Salk Institute. "In addition, the sheep is a good model for the human because the thyroid system of both species develops similarly during gestation. Prior to this study, we knew that, in general, fetal brain development requires thyroid hormones to grow normally and build all the right connections. We knew that children born to mothers who have low thyroid hormone levels are often retarded. These results show us that alcohol given to a
'"/>


15-Jan-2002


Page: 1 2 3

Related biology news :

1. Alcohol-use and depression among pregnant and postpartum women
2. Alcoholism risk linked to gene involved in brain chemistry
3. Alcohol consumption can damage hearing
4. Alcohol-dependence gene identified
5. Alcohol exposure in pre- and early post-natal stages may cause insulin resistance
6. Alcoholics with antisocial personality disorder have blunted emotional reactivity
7. Alcohols pharmacological properties, not smell or taste, reinforce its effects
8. Alcohol abuse may increase susceptibility to HIV infection
9. Alcohol researchers relate a genetic factor to anxiety in women
10. Alcohol researchers identify a genetic basis of pain response
11. Alcohols effects on testosterone

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Alcohol consumption during pregnancy alters thyroid function

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: